Get started
Alterity Therapeutics LimitedAlterity Therapeutics LimitedAlterity Therapeutics Limited

Alterity Therapeutics Limited

No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonals

Chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪61.67 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.0012 USD
Net income (FY)
‪−7.99 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪10.75 B‬
Beta (1Y)
1.25

Employees


Employees (FY)
9
Change (1Y)
−1 −10.00%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−887.57 K‬ USD

About Alterity Therapeutics Ltd.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David A. Stamler
Website
alteritytherapeutics.com
Headquarters
Melbourne
Founded
1997
IPO date
Mar 28, 2000
Identifiers
2
ISIN AU0000043945
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Check out other big names from the same industry as PRNAF.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of PRNAF is 0.0097 USD — it has decreased by −10.19% in the past 24 hours. Watch Alterity Therapeutics Limited stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Alterity Therapeutics Limited stocks are traded under the ticker PRNAF.
We've gathered analysts' opinions on Alterity Therapeutics Limited future price: according to them, PRNAF price has a max estimate of 0.02 USD and a min estimate of 0.01 USD. Watch PRNAF chart and read a more detailed Alterity Therapeutics Limited stock forecast: see what analysts think of Alterity Therapeutics Limited and suggest that you do with its stocks.
PRNAF reached its all-time high on Feb 28, 2014 with the price of 1.2600 USD, and its all-time low was 0.0001 USD and was reached on Jun 20, 2019. View more price dynamics on PRNAF chart.
See other stocks reaching their highest and lowest prices.
PRNAF stock is 11.34% volatile and has beta coefficient of 1.25. Track Alterity Therapeutics Limited stock price on the chart and check out the list of the most volatile stocks — is Alterity Therapeutics Limited there?
Today Alterity Therapeutics Limited has the market capitalization of ‪61.67 M‬, it has increased by 0.94% over the last week.
Yes, you can track Alterity Therapeutics Limited financials in yearly and quarterly reports right on TradingView.
Alterity Therapeutics Limited is going to release the next earnings report on Feb 26, 2026. Keep track of upcoming events with our Earnings Calendar.
PRNAF earnings for the last half-year are 0.00 USD per share, whereas the estimation was 0.00 USD, resulting in a 42.30% surprise. The estimated earnings for the next half-year are 0.00 USD per share. See more details about Alterity Therapeutics Limited earnings.
Alterity Therapeutics Limited revenue for the last half-year amounts to ‪4.18 M‬ USD, despite the estimated figure of ‪5.06 M‬ USD. In the next half-year revenue is expected to reach ‪1.01 M‬ USD.
PRNAF net income for the last half-year is ‪−3.27 M‬ USD, while the previous report showed ‪−4.44 M‬ USD of net income which accounts for 26.29% change. Track more Alterity Therapeutics Limited financial stats to get the full picture.
No, PRNAF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 14, 2026, the company has 9 employees. See our rating of the largest employees — is Alterity Therapeutics Limited on this list?
Like other stocks, PRNAF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alterity Therapeutics Limited stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Alterity Therapeutics Limited technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Alterity Therapeutics Limited stock shows the neutral signal. See more of Alterity Therapeutics Limited technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.